Description
Indication & Scope
EnZeShu® Suvemcitug for Injection treats adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Mechanism: It is a monoclonal antibody targeting specific tumor-associated antigens, which binds to tumor cell surface markers, mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity to eliminate malignant tumor cells.
- Drug class: Monoclonal antibody anti-tumor agent.
- Clinical use: First-line or maintenance targeted treatment for recurrent epithelial ovarian, fallopian tube and primary peritoneal malignancies in adults.
| Generic Name | Suvemcitug for Injection |
| Brand Name | EnZeShu |
| Ingredient | Suvemcitug |
| Dosage Form | Injection |
| Package | 50mg*1 vial/box |
| Conditions Treated | Recurrent ovarian cancer, recurrent fallopian tube cancer, primary peritoneal cancer in adult population |
| Taboos | Patients with confirmed severe hypersensitivity to Suvemcitug or any auxiliary components of the preparation |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store refrigerated at 2°C to 8°C, avoid freezing and direct sunlight |
| Manufacturer | XianSheng Biopharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20250037 |
| Approval Date | Jun 30, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Administer according to body weight; standard dose is given by intravenous infusion once every 3 weeks.
Time: Infusion shall be completed within 60–90 minutes, repeated every 21 days as a treatment cycle.
Instructions for use: Reconstitute the sterile powder with matching solvent, dilute with normal saline before slow intravenous infusion; premedicate with anti-allergic drugs to prevent infusion reactions.
Interaction: No definitive interaction data with chemotherapeutics; concurrent use of other immunotherapies requires close clinical monitoring.
Side effects:
1. Common: fatigue, nausea, hypoalbuminemia, infusion-related fever, peripheral edema.
2. Severe: severe anaphylaxis, neutropenia, liver function abnormality.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What are the main indications of Suvemcitug for Injection?
It is indicated for adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
What are the common side effects of Suvemcitug for Injection?
Common side effects include fatigue, nausea, hypoalbuminemia, infusion-related fever and peripheral edema.
What is the core anti-tumor mechanism of Suvemcitug for Injection?
It binds to tumor cell surface markers and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity to eliminate malignant tumor cells.
Who is prohibited from using Suvemcitug for Injection?
Patients with severe hypersensitivity to Suvemcitug or any auxiliary components of the preparation are contraindicated.
EnZeShu® | Suvemcitug for Injection | Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer | DengYueRX
INN: Suvemcitug for Injection
Indications: Ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Dosage Form: Injection
Strength: 50mg/vial
